Backed by Henri Termeer estate, Aura raises $30M for work to prevent blindness in eye cancer patients
Cambridge, MA biotech Aura Biosciences has raised $30 million in a Series C round to take its light-activated nanoparticle tech into late-stage trials for eye cancer.
With the new cash, Aura plans to finance its Phase Ib/II trial of the company’s lead therapy AU-011. The product candidate is being tested in patients with a rare eye cancer called ocular melanoma. Even though the cancer is often caught in its early stages, patients often go blind due to how the cancer is currently treated. Aura’s founder and CEO Elisabet de los Pinos tells me this eye cancer is currently treated with radioactivity since surgery is not possible.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.